GALDERMA
Galderma:
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN.
Galderma Group AG, the pure-play dermatology category leader, today announces the publication of its prospectus and the start of the book-building process, as part of its intention to conduct an Initial Public Offering on the SIX Swiss Exchange. To access the full announcement, please visit www.galderma.com/intentiontofloat.
About Galderma
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. Galderma’s portfolio of flagship brands includes Restylane, Dysport, Azzalure, Alluzience and Sculptra in Injectable Aesthetics; Cetaphil and Alastin in Dermatological Skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac and Loceryl in Therapeutic Dermatology. For more information: www.galderma.com.
The securities of Galderma Group AG have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312581535/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Market Update in Context of Moody’s Ratings Press Release18.2.2025 18:10:00 CET | Press release
SES S.A. has taken note of Moody’s Ratings Press Release today with regards to SES and is providing a market update ahead of its Full Year 2024 financial results announcement on 26 February 2025. SES expects Full Year 2024 Results(1) to be better-than-expected with Revenue at the top end of the financial outlook range (€1,940-2,000 million)(2) and Adjusted EBITDA above the outlook range (€950-1,000 million)(2). The proposed acquisition of Intelsat is on track to close during H2 2025. SES expects to reconfirm all financial targets for the combined company (pre-IRIS2) published in the transaction announcement in April 2024, including low- to mid-single digit average annual growth in Revenue for 2024-2028E, mid-single digit average annual growth in Adjusted EBITDA for 2024-2028E, and strong Free Cash Flow generation. SES remains committed to maintaining Investment Grade metrics. SES management looks forward to announcing its Full Year 2024 Results and discussing these, as well as its view
Planview Acquires Sciforma, Expanding Global Leadership in Portfolio Management Solutions18.2.2025 18:00:00 CET | Press release
Combined offerings support organizations at every Project Portfolio Management maturity level Planview®, the leading platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), today announced it has completed its acquisition of Sciforma, a prominent provider of Project Portfolio Management (PPM) and Product Development solutions. This strategic acquisition further solidifies Planview's position as the undisputed leader in enterprise portfolio management, bringing market-leading solutions to organizations at every PPM maturity level. "By acquiring Sciforma, we're strengthening our commitment to portfolio management practitioners worldwide," said Razat Gaurav, CEO of Planview. "Together, we're building the world's largest community of portfolio and product development professionals, delivering enterprise solutions that address their most critical challenges. No one in the market is better equipped to guide organizations through every stage of their portfolio
Armis Named a Leader in 2025 Gartner® Magic Quadrant™ for CPS Protection Platforms18.2.2025 17:30:00 CET | Press release
Armis supports global enterprises’ vast and varied needs to effectively secure critical CPS environments Armis, the cyber exposure management & security company, today announced that it has been named a Leader in the 2025 Gartner Magic Quadrant for CPS Protection Platforms. Cyber-physical system environments connect the physical and digital worlds, supporting sectors including infrastructure, transportation, healthcare and smart manufacturing. Their growing role increases risk due to complex IT, OT, IoT, and IIoT integrations that need robust security. We believe the Gartner Magic Quadrant for CPS Protection Platforms highlights the importance of protecting these systems. “Attacks on cyber-physical systems can disrupt operations and endanger lives, making their security our core mission, driven by innovation, expertise and customer collaboration,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “We believe being named a Leader in this report is a testament to the support that we prov
Italian Tennis Star Jasmine Paolini Joins Amazfit as Latest Athlete Ambassador18.2.2025 16:00:00 CET | Press release
Paolini to Wear Amazfit Smart Wearables to Enhance Performance and Recovery.Amazfit logo to appear on Paolini’s on-court apparel. Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), today announced the signing of Italian tennis sensation and World No. 4 Jasmine Paolini as its newest global athlete partner. As part of the multi-year agreement and official smart wearable partnership, Paolini will represent Amazfit by wearing the Amazfit logo and smartwatch on court and the brand’s fitness wearables, including Helio Ring, to track sleep and athletic recovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218222601/en/ Italian Tennis Star Jasmine Paolini Joins Amazfit as Latest Athlete Ambassador (Photo: Business Wire) Paolini is the current Italian No. 1 and highest-ranked Italian singles player in WTA history. She reached both singles and doubles finals at the 2024 French Open and was a singl
G2 Risk Solutions Acquires ZignSec AB for More Holistic Risk Management18.2.2025 15:06:00 CET | Press release
G2 Risk Solutions aims to bolster its footprint in Europe by acquiring ZignSec AB. G2 Risk Solutions (G2RS), a leading provider of risk management solutions in the financial sector, is announcing the acquisition of one of its affiliated companies of ZignSec AB (ZignSec). This marks a significant step forward in G2RS’ mission to deliver comprehensive, technology-driven compliance and risk solutions to regulated businesses worldwide. ZignSec AB provides cutting-edge identity verification solutions and owns Web Shield, a leader in merchant due diligence services, and Wyzer, a business process optimization and automation specialist. The collaboration among the three companies is expected to enable G2RS to enhance its portfolio of services and broaden its reach into critical areas of risk and compliance management globally. With this move, G2RS aims to strengthen its ability to serve highly regulated sectors, including financial institutions such as banks, lenders, creditors, merchant acqui
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom